Javed Butler, MD, MPH, MBA - How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/EYZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. SGLT2 inhibitors have a newly established role in the foundation of guideline-directed medical therapy for patients with heart failure (HF). As more data has been collected, these agents have evolved beyond their use in diabetes care, with SGLT2 inhibitors now earning a place as vital pharmacotherapy in optimizing the management of patients with HF. Landmark clinical trials of SGLT2 inhibitors have shown clinically relevant and statistically significant reductions in hospitalization for HF events, major adverse cardiovascular events, and kidney events. In this activity based on a recent live symposium, experts review the evidence for using SGLT2 inhibitors in patients with HFrEF, HfpEF, or acute HF, and provide guidance for integrating these multifaceted therapies into cardiology practice using a patient-centered approach. Upon completion of this activity, participants should be better able to: Identify patients with HF who are most likely to benefit from the use of SGLT2 inhibitors; Apply evidence for the use of SGLT2 inhibitors to optimize the management of patients with HF with or without comorbid conditions; and Integrate SGLT2 inhibitors for the treatment of patients with HF, considering indications, dosage, and other clinically relevant characteristics.